NP-184
NP-184 is a novel orally active antithrombotic agent. NP-184 selectively inhibits TXA2 synthase activity with an IC50 value of 4.3 μM. NP-184 has antiplatelet and antithrombotic activities. NP-184 can be used in the research of thromboembolic diseases[1].
Product Specifications
CAS Number
78706-11-3
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
Prostaglandin Receptor
Related Pathways
GPCR/G Protein
Field of Research
Cardiovascular Disease
Smiles
CC1=CC=C(C2=NC3=CC=CC=C3N2)O1
Molecular Formula
C12H10N2O
Molecular Weight
198.22
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362-P403+P233-P405-P501
References & Citations
[1]Kuo HL, et al. NP-184[2- (5-methyl-2-furyl) benzimidazole], a novel orally active antithrombotic agent with dual antiplatelet and anticoagulant activities. Naunyn Schmiedebergs Arch Pharmacol. 2010 Jun;381 (6) :495-505.
Shipping Conditions
Room temperature
Scientific Category
Reference compound2
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS6240770-01 0.1 mL
SSB (Sjogren Syndrome antigen B (Autoantigen La), LARP3, La) (MaxLight 750)
Sign In for Pricing
View Details MBS6240770-02 5x 0.1 mL
SSB (Sjogren Syndrome antigen B (Autoantigen La), LARP3, La) (MaxLight 750)
Sign In for Pricing
View Details 